VivoSeq
Oncology

Ductal Carcinoma in Situ

0

Pipeline Programs↗

4

Active Trials↗

1

Companies Involved↗

Ductal Carcinoma in Situ is an early-stage landscape with 0 programs across 1 company. The most active players are Radiation Therapy Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

27

clinical trials

Completed15 · 56%
Terminated4 · 15%
Recruiting3 · 11%
Unknown status3 · 11%
Withdrawn1 · 4%
Active, not recruiting1 · 4%

Clinical Trials

Trial Activity

27 trials

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Recruiting·MMayo Clinic·Phase 1·NCT04144023·43 enrolled
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT06075953·400 enrolled
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
Recruiting·—·Phase 1·NCT06218303·50 enrolled
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
Active, not recruiting·—·Phase 1·NCT02872025·42 enrolled
Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
Completed·—·Phase 2·NCT00256217·42 enrolled
Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ
Completed·Radiation Therapy Oncology Group logoRadiation Therapy Oncology Group·Phase 3·NCT00003857·636 enrolled
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Completed·National Cancer Institute (NCI)·Phase 3·NCT00769379·2,014 enrolled
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT01439711·108 enrolled
Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
Completed·QQueen Mary University of London·Phase 3·NCT00072462·2,980 enrolled
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
Completed·NNSABP Foundation Inc·Phase 3·NCT00053898·3,104 enrolled
Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
Completed·UUniversity of California, San Francisco·Phase 1·NCT00788112·17 enrolled
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast
Completed·—·Phase 1·NCT00107211·30 enrolled
Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)
Completed·UUniversity of California, San Francisco·N/A·NCT00804128·76 enrolled
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
Completed·NNorthwestern University·Phase 2·NCT02993159·100 enrolled
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
Completed·MM.D. Anderson Cancer Center·N/A·NCT00496808·69 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)